ANVISA Approves First Infliximab Biosimilar in Brazil
Hospira has announced that its partner, Celltrion — a global biopharmaceutical company — has received approval from ANVISA — the National Health Surveillance Agency in Brazil — for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil. The medication will be marketed by Hospira. Hospira also markets and sells biosimilar infliximab in 26 European countries and in Canada under the brand name Inflectra. This important product has been approved in Brazil for the treatment of: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's disease in adults and children, fistulizing Crohn's disease (advanced), colitis and ulcerative rectocolitis.
Remsima is the first biological medication approved by Brazil's regulator, ANVISA, based on comparability. A comparability study is required because under ANVISA's Normative Resolution RDC 55/2010, biosimilarity must be proven by direct comparison with the reference biological drug (products must be compared in a single clinical trial and using the same procedures). The study provided evidence of similarity between Remsima and the reference biological product, Remicade (infliximab).
"Biosimilars with comparative data of safety and efficacy are welcome by health professionals and also by the patients who use them. The effectiveness and safety of medications should be the foremost concern of those who manufacture, purchase and prescribe these drugs," said Valderilio Feijo Azevedo, a rheumatology specialist of the Brazilian Rheumatology Society and coordinator of the Brazilian and Latin American Forum for Biosimilars 2010–2014.
In a phase III trial involving 606 patients, Remsima achieved its main goal of treatment equivalence with Remicade. The trial showed that 73.4% of patients receiving Remsima achieved a 20% or better improvement in rheumatoid arthritis symptoms (based on American College of Rheumatology criteria) after 30 weeks of treatment, compared with 69.7% for Remicade.
During the same trial, 42.3% of patients receiving Remsima achieved a 50% or better improvement in rheumatoid arthritis symptoms (based on American College of Rheumatology criteria) after 30 weeks of treatment, compared with 40.6% for Remicade. Remsima also presents a similar safety and tolerance profile to Remicade.
"A robust package of comparative analyses involving Remsima and Remicade showing biosimilar infliximab's effectiveness and safety during rheumatoid arthritis treatment, as well as supporting data for ankylosing spondylitis, allowed us to extrapolate the data and gain approval from ANVISA to use the biosimilar in treatments for all approved indications of the reference product, without the need for additional clinical trials," said Sergio Teixeira, medical director for Hospira Brazil.
"We are looking forward to offering patients in Brazil better access to high-quality, effective and more affordable treatment options that can also help alleviate some of Brazil's rising healthcare costs," continued Teixeira.
Remsima and Inflectra were approved by the European Medicines Agency (EMA) in 2013 and are currently available in most European countries. Celltrion submitted an application to ANVISA to approve Remsima and Hospira will market the product exclusively in Brazil.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance